Angiosome-targeted vs non-targeted endovascular revascularization in diabetic foot ischemia: A retrospective cohort study

doi:10.4239/wjd.124667

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 11

This Article

(5)

(4)

(0)

(228)

Peer-Review Report of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Diabetes. Nov 15, 2026; 17(11): 124667
Published online Nov 15, 2026. doi: 10.4239/wjd.124667

Full Size Figure Download Figure

Figure 2 Clinical outcomes. Technical success, wound healing, limb salvage, and major amputation stratified by procedure group (targeted-only, non-targeted-only, and combined).

Citation: Zoghoul S, Obeidat M, Abdallah E, Al-Hashemi A, Shalaby R, Al-Hashimi I, El-Menyar A, Al-Thani H, Omar A, Barah A. Angiosome-targeted vs non-targeted endovascular revascularization in diabetic foot ischemia: A retrospective cohort study. World J Diabetes 2026; 17(11): 124667
URL: https://www.wjgnet.com/1948-9358/full/v17/i11/124667.htm
DOI: https://dx.doi.org/10.4239/wjd.124667

Zoghoul S, Obeidat M, Abdallah E, Al-Hashemi A, Shalaby R, Al-Hashimi I, El-Menyar A, Al-Thani H, Omar A, Barah A. Angiosome-targeted vs non-targeted endovascular revascularization in diabetic foot ischemia: A retrospective cohort study. World J Diabetes 2026; 17(11): 124667 [DOI: 10.4239/wjd.124667]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.